logo-loader

SFA Therapeutics developing its psoriasis therapy to showcase its anti-inflammatory platform

Published: 19:48 22 Oct 2019 EDT

SFA Therapeutics, Inc CEO Dr. Ira Spector sat down with Proactive at the BIO Investor Forum in San Francisco. The Pennsylvania-based company, using microbiome-derived metabolites as drugs, is advancing its oral treatment for psoriasis into Phase 2 clinical studies.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 30 minutes ago